Real‑world study of Cerviron® vaginal ovules in the treatment of cervical lesions of various etiologies

Biomed Rep. 2023 Jul 7;19(2):54. doi: 10.3892/br.2023.1618. eCollection 2023 Aug.

Abstract

Cervical lesions can be caused by pathogens, hormonal changes or by cervical injury. The recommended treatment in all cases is excision. Local re-epithelialization therapy should be initiated preoperatively and postoperatively. The present study assessed the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions postoperatively. The study population included 345 participants aged 20-70 years with either a cervical lesion under treatment or with recent surgical removal of a cervical lesion. The degree of re-epithelialization of the cervical mucosa was improved in 73.17% of the patients evaluated during routine colposcopy exams and 92.73% of patients recorded no bleeding. When adding Cerviron® either as monotherapy or in association with other antimicrobials in postoperative care of the cervical ectropion, improved postoperative outcomes such as reduced post-interventional bleeding and a superior quality of healing were observed. The study and its details are registered in www.clinicaltrials.gov under ID NCT05668806.

Keywords: cervical lesions; cervical mucosa; cervix re-epithelialization degree; medical device; vaginal bleeding; vaginal pH; vaginal pain.

Associated data

  • ClinicalTrials.gov/NCT05668806

Grants and funding

Funding: Perfect Care Distribution SRL (https://www.perfectcare.ro/), the study sponsor, offered the tested medical devices and a partial grant support.